Terminated trial tested combo for Tough-to-Treat GI cancers
NCT ID NCT05221320
Summary
This study tested whether combining two drugs, ulixertinib and hydroxychloroquine, could help control advanced gastrointestinal cancers that had specific genetic mutations and had stopped responding to standard treatments. It was designed for patients with cancers like pancreatic, colorectal, or stomach cancer who had already tried other therapies. The trial was terminated early and did not complete its planned enrollment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Massey Cancer Center, Virginia Commonwealth University
Richmond, Virginia, 23298, United States
-
Mount Sinai
New York, New York, 10029, United States
-
Rogel Cancer Center, University of Michigan Health
Ann Arbor, Michigan, 48109, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Arizona Cancer Center
Tucson, Arizona, 85719, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Kansas Cancer Center
Fairway, Kansas, 66205, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.